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Cupp†
Department of Animal Science, University of Nebraska-Lincoln, Lincoln, Nebraska 68583-0908
Abstract
Morphological male sex determination is dependent on migration of endothelial and preperitubular
cells from the adjacent mesonephros into the developing testis. Our hypothesis is that VEGFA and
its receptor KDR are necessary for both testicular cord formation and neovascularization. The
Vegfa gene has 8 exons with many splice variants. Vegfa120, Vegfa164, and Vegfa188 mRNA
isoforms were detected on Embryonic Day (E) 13.5 (plug date = E0) in the rat. Vegfa120, Vegfa144,
Vegfa164, Vegfa188, and Vegfa205 mRNA were detected at E18 and Postnatal Day 3 (P3). Kdr
mRNA was present on E13.5, whereas Fms-like tyrosine kinase 1 receptor (Flt1) mRNA was not
detected until E18. VEGFA protein was localized to Sertoli cells at cord formation and KDR to germ
and interstitial cells. The VEGFA signaling inhibitors SU1498 (40 μM) and VEGFR-TKI (8 μM)
inhibited cord formation in E13 testis cultures with 90% reduced vascular density (P < 0.01) in
VEGFR-TKI-treated organs. Furthermore, Je-11 (10 μM), an antagonist to VEGFA, also perturbed
cord formation and inhibited vascular density by more than 50% (P < 0.01). To determine signal
transduction pathways involved in VEGFA’s regulation of testis morphogenesis, E13 testis were
treated with LY 294002 (15 μM), a phosphoinositide 3-kinase (PI3K) pathway inhibitor, resulting
in inhibition of both vascular density (46%) and cord formation. Thus, we support our hypothesis
and conclude that VEGFA, secreted by the Sertoli cell, is involved in both neovascularization and
cord formation and potentially acts through the PI3K pathway during testis morphogenesis to elicit
its effects.
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INTRODUCTION
The formation of the seminiferous cords occurs on Embryonic Day (E) 13.5 in the rat (plug
date = E0) and is the first morphological indicator of testis differentiation [1,2]. Sry gene
expression by the Sertoli cell [3] induces the expression of other Sertoli cell-specific genes that
cause Sertoli-primordial germ cell aggregation and proliferation of Sertoli cells within the
indifferent testis [4,5]. Following this cellular aggregation, mesenchymal preperitubular cells
and endothelial cells migrate from the adjacent mesonephros into the differentiating testis to
envelop the Sertoli-germ cell aggregates [6,7]. The cell types that migrate from the
mesonephros into the testis are endothelial and preperitubular in origin [8]. It is not known
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how these mesonephric cells are induced to migrate into the testis, if they are pluripotent cells
that differentiate into multiple cell types, or if they are independent cell types that migrate due
to single or multiple growth factor signal transduction pathways [9,10]. Recent evidence
suggests that endothelial cells are potential precursors of Leydig cells [11], and granulosa cells
have many endothelial-like properties [12,13]. Therefore, it is possible that pre-endothelial
cells are necessary for the development of many different cell types within the gonads, in
addition to cell types comprising vasculature.
Removal of the mesonephros before mesonephric cell migration precludes cord formation.
Therefore, mesonephric cell migration appears to be crucial for testis development [6,7,14].
Mesonephric cells migrated through ovaries toward testis explants in mesonephric-ovary-testis
sandwich cultures [8], supporting the concept that a cell type in the testis induces mesonephric
cell migration. Because germ cell deficient mice have normal cord formation [15-17], the
Sertoli cells logically produce the paracrine growth factor(s) that induce mesonephric cell
migration [15-18]. Several factors, including the activity of Sertoli-derived chemokines, have
been proposed, because of alterations in seminiferous cord formation in vitro [19-23] and
altered testis morphogenesis in vivo [24,25].
At gonadal differentiation, another morphological event that occurs is development of sex-
specific vasculature [5,9]. Presently, it is unknown whether the testis vasculature develops at
the time of seminiferous cord formation or after testis morphogenesis. However, because both
pre-endothelial cells and pre-peritubular cells migrate into the differentiating testis as gonadal
morphogenesis is initiated [8], we hypothesized that both seminiferous cord formation and
vasculogenesis in the testis occur simultaneously. To test this hypothesis we chose to evaluate
whether VEGFA, because of its involvement in establishment of vasculature within other organ
systems, regulated testis morphogenesis.
The Vegf family is encoded by 5 different genes: Vegfa (Vegf), Vegfb, Vegfc, Vegfd, and
placenta growth factor. VEGFA (VEGF) is the most potent growth factor involved in
neovascularization of tissues and tumors. VEGFA acts through two receptors: FLT1 (also
known as VEGFR1) and KDR (also known as VEGFR2). Interaction between VEGFA and
KDR promotes the development of new vasculature in developing organs, whereas VEGFA
binding to FLT1 maintains and enhances survival of endothelial cells [26].
The Vegfa gene can undergo differential splicing to form many different isoforms. Five
isoforms are well documented (Vegfa205, Vegfa188, Vegfa164, Vegfa144, and Vegfa120),
whereas three of the isoforms (Vegfa188, Vegfa164, and Vegfa120) have been determined to
be expressed within most tissues of the body [27]. The function of VEGFA during embryonic
development is critical, because even the loss of one allele results in embryonic lethality before
testis development in transgenic mice [28,29]. Homozygous knockouts for either FLT1 or KDR
die on E9-10 before testis development [30,31], thereby preventing their use as a model in
these studies. Overexpression of VEGFA in transgenic mice is also detrimental to fertility and
embryonic viability [32,33]
The role of VEGFA and its receptors during embryonic testis morphogenesis has not been
investigated, nor has VEGFA been linked to regulation of events associated with cord
formation and sex-specific development of vasculature during testis morphogenesis.
Therefore, the objectives of the current study were to determine whether the angiogenic factor,
VEGFA, and its receptor, KDR, were important in testis morphogenesis.
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MATERIALS AND METHODS
RNA Isolation and Reverse Transcription of Vegfa Isoforms, and Kdr and Flt1 Receptor
mRNA
Total RNA was obtained from gonadal tissue of various developmental stages by using Tri
Reagent as per the manufacturer’s protocol (Sigma, St. Louis, MO). After isolation, total RNA
was resuspended to a volume of 20 μl, and 2.5 μl of this was reverse transcribed using
SuperScript II (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended
protocol [34]. The resulting cDNA was then stored at -20°C.
Primers
Primers for rat VEGFA were used to generate different PCR fragments, depending on the
Vegfa isoform expressed, namely a 431-bp product for Vegfa120, 500 bp for Vegfa144, 563
bp for Vegfa164, 635 bp for Vegfa188, and 750 bp for Vegfa205 [35]. Conventional PCR was
performed with Vegfa primers 5′-ctgctctcttgggtgcactg-3′ and 5′-caccgccttggcttgtcacat-3′ at an
annealing temperature of 58°C for 35 cycles. Human specific primers were used to amplify a
324-bp product for Flt1 (5′-caggctcatgaacttgaaagc-3′ and 5′-gaaggcatgaggatgagagc-3′) and a
213-bp product for Kdr (5′-caaaaattgtttctggggc-3′ and 5′-cagcttccaagcggctaagg-3′) [36] at an
annealing temperature of 56°C for 30 cycles for both sets of primers. Primers for rat Gapdh,
a constitutively expressed gene, were used to produce a 460-bp PCR fragment as a control for
RNA isolation and amplification [37]. Conventional PCR was performed with Gapdh primers
5′-accacagtccatgccatcac-3′ and 5′-tccaccaccctgttgctgta-3′ at an annealing temperature of 58°C
for 40 cycles. All PCR products were subcloned and confirmed using restriction digest analysis.
PCR products were subcloned into pCRII (Invitrogen Life Technologies) with the TOPO TA
Cloning kit (Invitrogen Life Technologies) and sequenced using primers provided with the kit
(data not shown).
Embedding, Histologic Analysis, and Immunohistochemistry
Tissues were fixed in Bouin’s solution and embedded in paraffin according to standard
procedures [34]. The tissues were sectioned (thickness, 5 μm), deparaffinized, rehydrated, and
microwaved in 0.01 M of sodium citrate for 5 min. After microwave treatment, tissues were
cooled for 1-2 h and rinsed in 3% hydrogen peroxide in methanol for 20 min. Sections were
then blocked with 10% normal goat serum in PBS for 30 min at room temperature.
Immunohistochemistry was performed as described previously [38]. The KDR antibody was
a mouse monoclonal IgG1 antibody (Santa Cruz Biotechnology [SCB], Santa Cruz, CA) raised
against a recombinant protein corresponding to amino acids 1158-1345 of KDR. The VEGFA
antibody was an affinity purified rabbit polyclonal antibody (SCB) raised against a peptide
corresponding to amino acids 1-140 of human VEGFA. Both antibodies were diluted
1:50-1:100 in 10% normal goat serum. As a negative control, serial sections were processed
without any primary antibody. The biotinylated goat anti-rabbit and goat anti-mouse secondary
antibodies were diluted 1:300. The secondary antibody was detected using aminoethyl
carbazole (AEC) chromagen substrate solution (ZYMED Laboratories, San Francisco, CA).
Sections were counterstained with hematoxylin to determine cell types that were stained with
respective antibodies.
Organ Cultures
Timed pregnant Sprague-Dawley rats were obtained from our breeding colony at the University
of Nebraska-Lincoln Animal Science Department, with founders being purchased from Charles
River Laboratories (Wilmington, MA). All animal procedures were approved by the University
of Nebraska Institutional Animal Care and Use Committee. The plug date was considered to
be E0. E13 gonads were dissected with the mesonephros. Only embryos with tail somite (ts)
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numbers between 15 and 18 were used for these experiments. One organ from each animal was
designated as a vehicle control, and its pair was subjected to VEGFA receptor signal
transduction antagonist, VEGFA antagonist treatment, or PI3K-inhibitor treatment. The organs
were cultured in drops of media on Millicell-CM filters (Millipore, Bedford, MA) floating on
the surface of 0.4 ml of CMRL Medium-1066 (Gibco, Grand Island, NY) supplemented with
penicillin-streptomycin, insulin (10 μg/ml), transferrin (10 μg/ml), L-glutamine (52 μg/ml),
and BSA (0.1%). Approximately 14-20 testis organ pairs were exposed daily to each of four
inhibitors at the following doses: VEGFR-TKI (VEGFA receptor antagonist [cat no. 676475]),
4 and 8 μM; SU1498 (KDR receptor antagonist), 20 and 40 μM; Je-11 (VEGFA antagonist),
10 μM; or 10 μM or 15 μM of the PI3K inhibitor LY 294002 (Calbiochem, La Jolla, CA). Each
inhibitor was added directly to the culture media while DMSO was added at a similar dose as
the treatment to paired vehicle controls. Media was changed once after 2 days of culture. Organs
were cultured for 3 days, by which point cords had developed in the controls. Only those organ
pairs whose control formed cords were used for analysis. We also determined that viability
was retained in our culture systems at each dose of inhibitor, because of no alterations in
labeling of mitotic germ cells for PECAM, as measured by the confocal microscope. The only
differences we detected in PECAM staining were in vasculature surrounding germ-Sertoli cell
aggregates. The concentration required for 50% inhibition (IC50) of VEGFR-TKI was 2.0
μM for FLT1 and 0.1 μM for KDR, as detected in cell cultures [39]. Because organ cultures
have 100 more cell layers than a cell culture system, our use of 4 and 8 uM was within
reasonable doses. The inhibitory strength of all other inhibitors used was less than the IC50
for cell cultures. A higher dose of Je-11 could not be used because the levels of DMSO
necessary in the final preparation of the compound would have impaired testis morphogenesis
in our controls.
Imaging and Area Analysis of Organ Cultures
All male organs, as confirmed by PCR for Sry expression in tail samples from each embryo
[20], were imaged before processing for whole-mount immunohistochemistry to verify the
presence of seminiferous cords in control organs and to analyze testis area. Brightfield images
of whole organs from the VEGFR-TKI and Je-11 treatments were obtained with a Spot camera
and Spot imaging capture system (Diagnostic Instruments; Spot Advance, Sterling Heights,
MI). Pixel areas were quantified using the NIH Scion image program (Scion Image, Frederick,
MD). Each testis (without mesonephros) was outlined twice, and the areas of these outlines
were averaged to obtain an accurate measurement. The averages for the control testis organ
cultures were set to 100%, and the area of each treated testis was calculated as a percentage of
its paired control, as described elsewhere [40].
Whole-Mount Immunohistochemistry of Organ Cultures
After imaging, the organs from the VEGFR-TKI experiment were fixed overnight at 4°C in
4% paraformaldehyde. Samples were washed in PBS for 2 h at room temperature (RT), placed
in blocking buffer (5% BSA, 0.1% Triton X-100, and PBS), and incubated overnight at 4°C,
followed by 1 h at RT. Samples were then incubated overnight at 4°C with anti-PECAM1
antibody (Pharmingen, San Diego, CA; 1:50 dilution in blocking buffer), then rinsed with
washing buffer (1% BSA, 0.1% Tween 20, and PBS) for 4-5 h at 4°C (changing the buffer
once), followed by two 1-h rinses at RT. Samples were incubated overnight at 4°C with Cy5-
conjugated secondary antibody (Jackson Laboratories, West Grove, PA; 1:500 in blocking
buffer), then rinsed with washing buffer as described above. The above blocking, incubation,
and washing steps were repeated using an anti-laminin primary antibody (DAKO, Carpinteris,
CA; 1:100) and a Cy2-conjugated secondary antibody. Primary antibodies to PECAM1
(Pharmingen, San Diego, CA) and laminin (DAKO, Carpinteris, CA) were selected because
they stain endothelial cells and basement membrane, respectively [41,42], allowing for
visualization of vasculature and seminiferous cords.
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The whole-mount immunohistochemistry procedure for the Je-11-treated organs was slightly
modified to use Alexa Fluor secondary antibodies, in accordance with previously reported
methods [43]. Organs were fixed in 4% paraformaldehyde for 1 h at RT [44], followed by two
5-min rinses in washing buffer (WB-PT) (1× PBS with 0.1% Triton X-100; Sigma, St. Louis,
MO) and an additional 1-h rinse at RT. Tissues were then blocked in blocking buffer 1 (BB1)
(WB-PT with 5% BSA; Invitrogen, Carlsbad, CA) for 1 h. Primary antibodies were diluted
1:50 in BB1 and incubated with gonads overnight at 4°C. On the second morning, organs were
rinsed three times in blocking buffer 2 (BB2) (WB-PT with 1% BSA) for 30 min at RT before
incubation with secondary antibodies Alexa Fluor 488 and Alexa Fluor 647 (1:200 in BB1;
Molecular Probes, Eugene, OR) for 3-4 h at RT. Samples were then washed again in BB2 four
times (30 min per wash), followed by a final rinse with 1× PBS.
All whole-mount immunohistochemistry samples were mounted in Gel/Mount (Biomeda,
Foster City, CA) for subsequent confocal microscopy.
Confocal Microscopy of Organ Cultures
Images from the VEGFR-TKI whole-mount immunohistochemistry experiments were
collected using a BioRad MRC1024ES confocal laser scanning microscope (Hercules, CA).
Organs were scanned through a series of Z-sections from their dorsal to ventral surfaces at
magnifications of 100×, 200×, and 600× (thickness of sections, 10, 5, and 3 μm, respectively)
with green, red, and merged channels, respectively, to determine staining for PECAM and
laminin. Organ depths were estimated at a magnification of 100× by the number of 10-μm Z-
steps required to scan through the entire organ.
Images from the Je-11 and PI3K inhibitor (LY 294002) whole-mount immunohistochemistry
experiments were collected using an Olympus FluoView 500 confocal laser scanning
microscope. Organs were imaged and analyzed at magnifications of 100×, 200×, and 400× for
morphological structures. We scanned throughout the depth and length of each organ to ensure
that images were representative of gonadal morphogenesis. Organs were scanned from their
dorsal to ventral surfaces at a magnification of 100× to determine organ depth. Depths were
calculated for treated and control organs by the number of 3-μM sections required to scan
through the entire organ. Images were taken with green, red, and merged channels open to
determine staining for laminin, PECAM, and merged images, respectively.
Vascular Density Quantification
Red channel confocal images at 600× magnification were used to analyze the vascular density
of control and VEGFR-TKI treated organ cultures and 400× magnification for Je-11-treated
and P13K inhibitor organ cultures. Staining index (SI) was quantified with the use of Scion
imaging. Densitometry was performed on 1-4 fields for each organ. Within each field, the SI
was defined as the number of pixels exceeding an arbitrary grayscale value. The average SI
for each organ was defined as the mean of the SIs for the fields measured. The mean vascular
density value (i.e., SI) for each control testis organ culture was set to 100%, and the mean of
each treated testis was calculated as a percentage of its paired control. Approximately 14 testis
pairs were imaged for vascular density quantification for VEGFR-TKI, Je-11, and P13K
inhibitor experiments.
Statistical Analysis
The mean value for each parameter evaluated in the control testis was set to 100%, and the
mean of each treated testis was calculated as a percentage of its paired control. An analysis of
variance was conducted to detect any statistical differences between means of the treated and
control testes during analysis of vascular density, testis area, and organ depth, using JMP
software (SAS Institute, Cary, NC). Dunnett test was then used to compare the percentage of
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control to treated organs. Differences in data were considered to be statistically significant at
a P value of <0.05, unless otherwise stated.
RESULTS
Pattern of Expression of mRNA for Vegfa Isoforms, Kdr, and Flt1 During Testis Development
Vegfa188, Vegfa164, and Vegfa120 mRNA were detected with conventional RT-PCR at E13
(Figure 1A). These three mRNA isoforms continued to be present until E18 during embryonic
testis development. Five isoforms for Vegfa mRNA (Vegfa205, Vegfa188, Vegfa164,
Vegfa144, and Vegfa120) were detected at E18 and continued to be expressed at P3 (Figure
1A). Thus, Vegfa188, Vegfa164, and Vegfa120 mRNA were present around the time of
seminiferous cord formation and may be involved in processes regulating the development of
these morphological structures.
Conventional RT-PCR was conducted from E14 through E18 in the rat to determine whether
receptors for VEGFA were present during embryonic testis development. Kdr mRNA was
detected at all time points from E14 through E18 (Figure 1B). However, Flt1 mRNA expression
was not detected until E18. Therefore, the predominant action of VEGFA during embryonic
testis development (neovascularization and morphogenesis [i.e., cord formation]) occurs
through KDR (Figure 1B).
Localization of VEGFA and KDR
Immunohistochemistry was conducted from E14 through Postnatal Day (P) 5 to determine cell
types expressing VEGFA and KDR during early testis morphogenesis. VEGFA expression
was detected at E14 mainly in Sertoli cells (Figure 2, A and B), with some expression in germ
cell cytoplasm within the seminiferous cords and in specific interstitial cells within the
interstitium. Because the majority of the staining was detected within the nonvascularizing
seminiferous cords, VEGFA may be involved in Sertoli-germ cell interactions that are
independent from the usual angiogenic actions of VEGFA.
VEGFA staining was still present in the seminiferous cords at E16 (Figure 2, C and D), with
more intense staining in Sertoli cells surrounding germ cells. Additional staining was detected
within cells of the interstitium. By E19, VEGFA staining was still present in the cords, with
less intense staining in the Sertoli cells and more intense staining in germ cell cytoplasm (Figure
2E). Certain interstitial cells also stained for VEGFA. In P0 testis, the pattern of VEGFA
staining was similar to that in E19 testis (Figure 2F), except only specific germ cells had
elevated levels of VEGFA staining in the cytoplasm at this age. By P5 (Figure 2G), Sertoli
cells had markedly increased staining intensity, compared with earlier ages. VEGFA remained
localized around specific germ cells. No staining was detected in the negative control E16 testis
that was processed without primary antibody (Figure 2H).
KDR staining was present in seminiferous cords with some staining in interstitial cells (Figure
3, A and B) at E14. Interstitial cells, as well as Sertoli cells within seminiferous cords in E19
tissues (Figure 3C), were clearly expressing KDR protein. Interstitial cells, Sertoli cells, and
cytoplasm of germ cells expressed KDR protein at P0 and P5 (Figure 3, D and E), whereas no
expression was detected in E16 control testis sections that were processed without primary
antibody (Figure 3F).
Effects of VEGFA Signal Inhibitors on Testis Morphogenesis in Organ Cultures
Treatment of E13 testis organ cultures with a VEGFA receptor signal transduction inhibitor,
VEGFR-TKI (8 μM; Figure 4), severely perturbed (in 2 treated organs; Figure 4D) or totally
inhibited (in 12 treated organs; Figure 4B) seminiferous cord formation, compared with the
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findings for controls (Figure 4, A and C). There was no effect of VEGFR-TKI on testis
morphogenesis at the 4-μM dose (data not shown). To further confirm KDR involvement,
SU1498 (a specific signal transduction inhibitor for KDR) was administered at two doses (20
and 40 μM). There were no identifiable effects of SU1498 at 20 μM (data not shown); however,
at 40 μM, SU1498 inhibited or severely perturbed seminiferous cord formation (Figure 4F),
compared with the response in controls (Figure 4E).
To characterize the effects of the VEGFA signal transduction inhibitor, VEGFR-TKI, the area
of testis organ cultures were measured, and treated organs were found to have a 23% reduction
in size (P < 0.01; 100% vs. 77% ± 10%), compared with their paired controls. Furthermore,
depth of organ cultures (detected by number of Z series confocal microscopy images conducted
on each organ) was also reduced (by 21%) in the VEGFR-TKI-treated testis organ cultures
(P < 0.01; 79% vs. 100% ± 2.3%), compared with their paired controls. Thus, it appears that
disruption of VEGFA receptor signal transduction impairs the ability of seminiferous cords to
form and reduces the area of the gonad.
In addition to evaluating the presence or absence of seminiferous cords, an objective of the
current experiment was to determine the effects on vascular development in relation to
seminiferous cord formation. After organ cultures were imaged for brightfield analysis, whole-
mount immunohistochemistry was conducted for laminin (to determine the presence of
seminiferous cords) and for PECAM (to determine alterations and patterns in vascular
development). Confocal microscopy analysis demonstrated that control organ cultures had
laminin staining (green; Figure 5, A-C), which outlined seminiferous cords, and PECAM-
stained vascular tissue (red), which surrounded the seminiferous cords. Furthermore, at higher
magnifications, mitotic germ cells within seminiferous cords also stained for PECAM (Figure
5C). In contrast, the treated organ was smaller, and there were no organized seminiferous cords
(depicted by green basement membrane staining) or patterns of vascular development when
viewed at higher magnifications (Figure 5, D-F). Also, because mitotic germ cells stain for
PECAM, it was inconclusive whether endothelial cells were even present within the treated
testis organ culture.
To quantify vascular density within control and VEGFR-TKI-treated organs, red channel
confocal images at 600× magnification were evaluated in conjunction with Scion imaging.
Three areas within all 14 testis pairs were imaged, and there was a 90% reduction in vascular
density in VEGFR-TKI-treated organs, compared with paired control organs (P < 0.01; 10%
vs. 100% ± 0.7%).
Effect of VEGFA Inhibitor, Je-11, on Testis Morphogenesis in Organ Cultures
To determine whether blocking VEGFA binding to its receptor would have similar effects as
the VEGFA receptor signal transduction inhibitors, we used a VEGFA inhibitor, Je-11, which
binds VEGFA and prevents it from binding to its receptor in testis organ cultures. At a 10-μM
dose, Je-11 perturbed cord formation, resulting in abnormal or no cord formation (Figure 4, H
and I), compared with controls (Figure 4G). Testis area (P = 0.63; n = 14 pairs) and depth (P
= 0.28) were unaffected by treatment.
Normal vascular patterns, as determined by the presence of PECAM staining [45], were present
in control organs surrounding seminiferous cords (Figure 5, G-I) and in the coelomic vessel
(Figure 5, J-L). However, vasculature in treated organs was less dense, consisting of smaller
microvessels (Figure 5, M-O). Vascular density, as indicated by PECAM expression, was
reduced 42% in Je-11-treated organs (P < 0.01; 100% vs. 58% ± 10%; n = 13 organ pairs).
Mitotic germ cells, as indicated by PECAM expression, were present in both treated and control
testes (Figure 5, G-O). Therefore, differences in vascular density (PECAM staining) were
attributed to modifications in vascular development.
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Inhibition of PI3K Prevents Vasculogenesis and Cord Formation
The PI3K inhibitor LY 294002 was used to investigate VEGFA signal transduction pathways
and whether the PI3K pathway was important for neovascularization and cord formation during
testis development. E13 rat testes (n = 13 pairs for each dose) were either treated with 10 or
15 μM of LY 294002 or served as vehicle controls for a 3-day culture and were analyzed for
cord formation, testis depth, area, and PECAM staining density. Seminiferous cords developed
normally in all controls. No differences in testis depth (P = 0.21; n = 13), area (P = 0.086; n =
13), or overall vascular (PECAM) density (P = 0.17; n = 13) resulted from treatment with 10
μM of LY 294002. However, cords in treated organs appeared smaller and irregular in shape
in response to the inhibitor at both doses (Figure 6, B and D), compared with the corresponding
controls (Figure 6, A and C). Testis depth was not affected by 15 μM of LY 294002 treatment
(P = 0.62; n = 15 pairs), but testes area was reduced by 23.8% (P < 0.01; n = 14 pairs), compared
with vehicle controls.
Analysis of PECAM expression revealed the presence of organized mitotic germ cells and
vasculature throughout treated and control testes (Figure 7, A-F). Distinct vascular patterns
were organized around seminiferous cords in control testes (Figure 7, B and C) but were lacking
in treated testes (Figure 7, E and F). Scion imaging revealed higher vascular (PECAM) density
in control organs than in those treated with 15 μM of LY 294002. In fact, vascular (PECAM)
density was reduced by 46%, compared with that in controls (P < 0.01; n = 15) (Figure 7). At
the 15-μM dose, the LY 294002 PI3K inhibitor affected normal testis cord morphologic
characteristics and reduced vascular density. Thus, blocking the PI3K signal transduction
pathway arrests both cord formation and vascular density.
DISCUSSION
Although the role of many growth factors have been investigated and implicated in testis
morphogenesis, data from the current study support that VEGFA and KDR are involved in
both neovascularization and seminiferous cord formation in the embryonic testis. Potentially,
these effects are mitigated through the PI3 kinase pathway. These experiments are also the first
to support the notion that vascular development and seminiferous cord formation may be
dependent events during testis development. Furthermore, we also provide evidence supporting
the concept that VEGFA, a Sertoli-cell secreted factor, potentially directs mesonephric cell
migration, resulting in the formation of seminiferous cords and development of sex-specific
patterns of vasculature.
Vascular development within the testis does not appear to be dependent on Sry, because male
patterns of vascular development can form in XX Wnt4 knockout mice (Wnt4-/-) [46]. Also,
overexpression of Wnt4 in XY gonads disrupts vascular development [47]. It is proposed that
expression of Sry antagonizes Wnt4 and the gene encoding follistatin (downstream from
Wnt4) to allow for endothelial cell migration and formation of male-specific vascular
development during testis morphogenesis. In the current study, we determined that several
Vegfa gene isoforms are expressed in the indifferent gonad. We propose that regulation of
expression of VEGFA and its receptors, KDR and FLT1, may be modified by genes
differentially expressed in the XX versus XY gonad to elicit sex-specific vascular patterns.
Hypoxia [48-50], estradiol [51,52], progesterone [53], and factors signaling through the BMP/
SMAD pathway [54,55] have all been implicated in increased or decreased expression of
VEGFA. The Vegfa gene contains eight exons, which, through alternative splicing, can produce
many VEGFA isoform proteins that have angiogenic and antiangiogenic properties. In the
current study, the three mRNA isoforms Vegfa120, Vegfa164, and Vegfa188 were expressed
during seminiferous cord formation. These three isoforms have different diffusion affinities,
because of the absence or presence of one or multiple heparin binding domains. Thus, they
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potentially work together, presumably in the absence of Wnt4 expression, as a chemoattractant
gradient to induce and recruit mesonephric endothelial cell migration into the developing testis
establishing male-specific vascular development [56-59]. VEGFA appears to work through
KDR to cause neovascularization of the testis. In the current study, mRNA for Flt1 was not
expressed until E16 of testis development, well after seminiferous cord formation, whereas
Kdr was present throughout all embryonic time points evaluated. Similarly, in other tissues
and organs, KDR is the primary receptor that facilitates VEGFA-induced neovascularization
[60].
In addition to Vegfa120, Vegfa164, and Vegfa188, other Vegfa mRNA isoforms (Vegfa144 and
Vegfa205) appeared by E18 within the embryonic testis. The presence of these other isoform
bands suggests that alternative splicing occurs after E18 to produce a greater number of
Vegfa isoforms. Several events occur at this time during rat testis development. Steroidogenic
enzymes, such as hydroxysteroid dehydrogenase 3-β and aromatase, appear in differentiating
Leydig cells within the rat during E15-16 [61]. The Vegfa promoter region has been
demonstrated to have several nonconcensus ERE binding sites, and both estrogen and
progesterone treatment in breast cancer and uterine cells has altered expression of Vegfa mRNA
isoforms [52]. Therefore, steroid hormones expressed at this time during testis development
may alter expression of specific Vegfa isoforms.
A second possibility is that VEGFA may be involved in germ-Sertoli cell interactions leading
to maturation of germ cells. At E16.5 in the mouse (which translates to E17-18 in the rat),
gonocytes (specific stage germ cells) undergo mitotic arrest in the G0/G1 phase of the cell
cycle [62]. Other investigators have determined that VEGFA may be important in germ cell
survival and development, because expression of VEGFA receptors are localized to specific
stages of germ cells in late gestation and early postnatal development [63]. VEGFA [63],
prokineticin 1 (also known as EG-VEGF), and prokineticin 2 (formerly known as Bv8)
[64-66] have all been demonstrated to be involved in germ-Sertoli cell interactions in the
postnatal testis. Therefore, it is possible that, after sex-specific vasculature has formed, VEGFA
is primarily involved in germ cell maturation/survival mechanisms occurring during
spermatogenesis.
In the current study, VEGFA protein expression was localized to the testicular cords and,
specifically, the Sertoli cells early in testis development. This finding is significant, because
the Sertoli cell is the first cell to differentiate in the testis and has been proposed to regulate
genes controlling testis differentiation [4,5]. Endothelial and pre-endothelial cells express KDR
[60]. Thus, one purpose of Sertoli cell secretion of VEGFA may be to induce endothelial cells
or endothelial cell precursors to migrate into the differentiating testis to aid in
neovascularization and cord formation. Other growth factors, such as PDGFA, have been
demonstrated to be important for male specific cell migration [23]. Although VEGFA is
thought to be critical to endothelial cell migration [26,67], PDGFA is thought to cause
migration of pericytes that form a smooth muscle layer around blood vessels to support and
maintain the integrity of vasculature [68-70]. It is possible that pre-endothelial cells are
migrating toward a concentration gradient of VEGF and that, as these cells migrate, they
differentiate into endothelial and preperitubular cell types that allow for seminiferous cord
formation and sex-specific vasculature to develop.
Another purpose of VEGFA during cord formation may be to allow for differentiation of
endothelial cells into arterial networks. Before cord formation in the mouse (on E11.5), pre-
endothelial cells express markers for both venous (EPHB4) and arterial (ephrin B2) markers.
However, just after E11.5, a rapid reorganization of vasculature occurs within the testis to form
arterial networks, which surround the developing seminiferous cords and coelomic blood
vessel [71]. Thus, after cord formation, the testis is mainly composed of arterial networks
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instead of veins. Several scientists have established that VEGFA is the main growth factor
involved in differentiating endothelial cells into arterial networks [72,73]. Therefore, in
addition to establishing a vascular network, VEGFA may also act to induce endothelial cells
to differentiate into arteries forming the arterial network present after cord formation.
Inhibition of VEGFA’s action through a VEGFA receptor signal transduction inhibitor,
VEGFR-TKI (which blocks the actions of both FLT1 and KDR), inhibited seminiferous cord
formation in testis organ cultures and inhibited sex-specific vascular development.
Furthermore, a KDR-specific inhibitor arrested cord formation. The fact that both inhibitors
yielded similar results was expected, because the only receptor detected during cord formation
was KDR. To further support VEGFA’s role in testis morphogenesis, a VEGFA antagonist,
Je-11, also impaired normal cord formation and reduced vascular density, as measured by
PECAM staining. Je-11 acts to inhibit VEGFA from binding to its receptors. Therefore, sex-
specific vascular development, vascular density, and seminiferous cord formation were
inhibited when VEGFA signal transduction or binding to its receptor was prevented.
The PI3K signal transduction pathway has been implicated in many different systems to be
important in VEGFA mediated endothelial cell survival, proliferation, and migration [74-77].
Previous research has demonstrated that the PI3K specific inhibitor, LY 294002, inhibits
seminiferous cord formation in rat testis cultures. Cell migration assays revealed that testis
morphogenesis impaired by LY 294002 was due to inhibition of mesonephric cell migration
[78]. Because inhibition of VEGFA perturbed cord formation and vascular development, we
sought to determine whether inhibition of the PI3K signal transduction pathway would also
affect vascular development in addition to seminiferous cord formation. PI3K inhibition
reduced vascular density and testis area and perturbed cord formation in a manner that was
similar to our results of VEGFA signal transduction and antagonist inhibition. Thus, we believe
that these studies provide correlative data to demonstrate that VEGFA may work predominately
through the PI3K pathway to elicit its effects during testis morphogenesis. Furthermore,
because both cord formation and vascular development is arrested by inhibition of PI3K, this
further links these two morphogenic events through a single signal transduction pathway.
VEGFA is not the only growth factor that elicits its effects through the PI3K pathway.
Neurotrophin 3 [21,78] and PDGFA [78-80] have all been implicated to act through PI3K to
elicit their effects. Thus, multiple growth factors may work through PI3K in order to contribute
to regulation of testis morphogenesis.
In conclusion, the current studies demonstrate that VEGFA and its receptor KDR are expressed
at the time of testis morphogenesis (i.e., seminiferous cord formation and sex-specific vascular
development). VEGFA is expressed by Sertoli cells and other cells within the seminiferous
cords early in development, with expression of KDR occurring in the cords and in cells that
we suspect to be the developing vasculature. The importance of VEGFA in testis formation
was underscored by the disruption of both seminiferous cord formation and vascular
development in testis organ cultures following treatment with specific VEGFA inhibitors and
VEGFA receptor signal transduction inhibitors. These studies establish a role for VEGFA in
vascular development during testis morphogenesis and also support coordinate regulation of
cord formation and sex-specific vascularization through the PI3 kinase pathway.
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Figure 1.
Conventional RT-PCR for VEGFA isoforms from Embryonic Day (E) 13 to Postnatal Day 3
of testis development (A) and Kdr and Flt1 from E14 through E18 of testis development (B).
Negative controls (not shown) had no template and did not result in a band. RT-PCR was
conducted on three to five different samples for each time point during testis development.
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Figure 2.
Immunohistochemistry for VEGFA in Embryonic Day (E) 14 testis (magnification, ×200)
(A), E14 (×400) (B), E16 (×400) (C), E16 (×200) (D), E19 (×400) (E), P0 (×400) (F), and
Postnatal Day 5 (×400) (G). E16 sections with no primary antibody (F) served as negative
controls. These results are representative images from 3 different experiments conducted with
three to six different sections of tissue from each age group. T = testis; M = mesonephros; c =
cord; i = interstitium; S = Sertoli; G = germ.
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Figure 3.
Immunohistochemistry for KDR (VEGFR2) expression in testes at Embryonic Day (E) 14
(magnification, ×200) (A), E14 (×400) (B), E19 (×400) (C), Postnatal Day (P) 0 (×400) (D),
and P5 (×400) (E). E16 controls with no primary antibody (F) served as negative controls.
These results are representative images from three different experiments conducted with three
to six different sections of testis tissue from each age group. T = testis; M = mesonephros; c =
cord; i = interstitium; S = Sertoli; G = germ. Arrows point to Sertoli and germ cells.
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Figure 4.
Effect of the VEGFR signal transduction inhibitors VEGFR-TKI, SU1498, and Je-11 on
seminiferous cord formation in organ cultures of rat testis obtained on Embryonic Day 13.
Organ cultures contained vehicle controls (DMSO) (A, C, E, G) or specimens treated daily
with 8 μM of VEGFR-TKI (B, D), 40 μM of SU1498 (F), or 10 μM of Je-11 (VEGFA
antagonist) (H, I). T = testis; M = mesonephros.
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Figure 5.
Whole-mount immunohistochemistry of Embryonic Day 13 testis organ culture controls for
VEGFR-TKI treatments (A, B, C), testis cultures treated with 8 μM VEGFR-TKI (D-G),
vehicle controls for VEGFA antagonist Je-11 (G-L), and testis cultures treated with 10 μM
Je-11 (M-O). Cultured organs were labeled with antibodies against laminin (green, basement
membrane marker) and PECAM (red, endothelial cell and mitotic germ cell marker). Note that
only mitotic germ cells express PECAM; germ cells that are not mitotic do not express PECAM.
A representative control organ (A-C), shows both blood vessel patterns (arrows, B) and
seminiferous cord formation (arrows, C). Mitotic germ cells can be seen within the
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seminiferous cords (*, C). Organs treated with 8 μM VEGFR-TKI (D-F) do not have normal
vasculature patterns or cord formation.
Magnifications are ×100 (A, D), ×200 (B, E), and ×600 (C, F, G). Normal vascular patterns
surrounding seminiferous cords within the testis are detected in vehicle controls for Je-11 at
magnifications of ×100 (G, J), ×200 (H, K), and ×400 (I, L). At high magnifications (I, K,
L), mitotic germ cells (arrows) have organized into cord-like structures and are surrounded by
vasculature. The coelomic vessel also expressed PECAM (K, L). In Je-11-treated testes, germ
cells are clustered together into smaller, irregular cord patterns with reduced vascular density
at magnifications of ×100 (M), ×200 (N), and ×400 (O). T = testis; M = mesonephros; c =
cord; CV = coelomic vessel. Dashed lines indicate the boundary between the testis and
mesonephros.
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Figure 6.
Effects of LY 294002 on organ cultures rat testis obtained on Embryonic Day (E) 13. Cultured
testes from E13 rats treated with DMSO vehicle control (A, C) developed normal seminiferous
cords, whereas testes treated with 10 μM (B) or 15 μM (D) of the PI3K inhibitor LY 294002
developed smaller and occasionally swollen cords (B) or had perturbed cord formation (D). T
= testis; M = mesonephros.
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Figure 7.
Effect of 15 μM of LY 294002 on whole-mount immunohistochemistry on Embryonic Day 13
rat testis and mesonephros organ cultures. A representative control organ (A-C) with germ
cells is organized within cords surrounded by vasculature (arrows). The treated testis (D-F) is
smaller than the control, and germ cells are not as clearly organized within cords. Vasculature
surrounds these cords (F) but is less abundant than that in paired control testes. T = testis; M
= mesonephros; c = cords.
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